Semaglutide and Liraglutide are both approved GLP-1 receptor agonists, both from Novo Nordisk, and both built on the same idea: take a hormone the body destroys in about two minutes and make it last. The difference between them is not which receptor they hit — it is how much longer the chemists managed to make the second one last. Liraglutide stretched native GLP-1 to a 13-hour plasma half-life, enough for once-daily injection. Semaglutide stretched it to roughly one week. Everything else that separates them in the clinic follows from that engineering gap. This page describes what the trials measured; it is not dosing guidance or a treatment recommendation.
Head-to-head at a glance
| Dimension | Semaglutide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist; glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, central appetite signalling | GLP-1 receptor agonist; same four described actions, same single receptor target |
| Protraction chemistry | C18 fatty di-acid on Lys26 via a hydrophilic spacer, >99% albumin-bound, plus a position-8 substitution that blocks DPP-4 cleavage | C16 palmitoyl chain, >98% protein-bound, self-association plus albumin binding; no DPP-4-blocking backbone change |
| Half-life / frequency | ≈1 week; once-weekly injection (oral tablets are once-daily) | ≈13 hours; once-daily injection |
| Brands and US indications | Ozempic (type 2 diabetes, MACE reduction, CKD progression); Wegovy (weight reduction, MACE reduction, MASH with F2–F3 fibrosis); Rybelsus / Ozempic tablets (type 2 diabetes) | Victoza (type 2 diabetes from age 10, MACE reduction in established CV disease); Saxenda (weight reduction from age 12) |
| Head-to-head, diabetes | SUSTAIN 10 (n=577): 1.0 mg weekly cut HbA1c 1.7% and weight 5.8 kg | SUSTAIN 10: 1.2 mg daily cut HbA1c 1.0% and weight 1.9 kg (differences −0.69% and −3.83 kg, both P<0.0001) |
| Head-to-head, obesity | STEP 8 (n=338, 68 weeks): 2.4 mg weekly, −15.8% body weight; 38.5% lost ≥20% | STEP 8: 3.0 mg daily, −6.4%; 6.0% lost ≥20% (difference −9.4 points, 95% CI −12.0 to −6.8) |
| Standalone trial anchors | STEP 1 (n=1,961): −14.9% vs −2.4% placebo over 68 weeks | SCALE (n=3,731): −8.4 kg vs −2.8 kg placebo over 56 weeks |
| Cardiovascular outcomes | SELECT (n=17,604, obesity without diabetes): MACE 6.5% vs 8.0%, HR 0.80 (95% CI 0.72–0.90) | LEADER (n=9,340, type 2 diabetes): MACE 13.0% vs 14.9%, HR 0.87 (95% CI 0.78–0.97); CV death HR 0.78 |
| Safety framing | Boxed warning for rodent thyroid C-cell tumors; contraindicated with personal/family MTC or MEN 2; pancreatitis and gallbladder warnings | Same boxed warning, same contraindications, same class warnings — this row is where the two molecules differ least |
| Oral availability | Yes — co-formulated with SNAC absorption enhancer; absolute bioavailability ≈0.4–2% | No oral formulation approved; injection only |
| Generic status | No US generic; brand-only | First generic referencing Victoza approved December 2024 — the first once-daily GLP-1 generic |
One receptor, two generations of chemistry
Native GLP-1(7-37) has a half-life of 1.5 to 2 minutes, degraded by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases. Liraglutide answered that problem with a single trick: attach a C16 fatty-acid chain so the molecule self-associates and binds reversibly to albumin, which slows renal clearance and shields it from enzymes. The result is a molecule that is more than 98% protein-bound and clears with a half-life of about 13 hours.
Semaglutide applied the same principle harder, and added a second one. Its label describes three modifications: a C18 fatty di-acid attached at position 26 through a hydrophilic spacer (stronger, more specific albumin binding — more than 99% bound), a substitution at position 8 that stabilises the peptide against DPP-4 cleavage directly, and a minor position-34 change so only one fatty di-acid attaches. Lifting albumin affinity while removing the enzymatic cut site moved the half-life from hours to a week. Knudsen and Lau's 2019 discovery review traces that search — systematically varying fatty-acid chain length and linker to maximise albumin binding without losing receptor potency — and it is the clearest published account of why two drugs with the same target behave so differently.
The practical consequence beyond convenience: a weekly agent holds steadier plasma concentrations, where a daily agent peaks and troughs every 24 hours. That is the mechanistic hypothesis usually offered for why the head-to-head results split the way they do.
The two direct comparisons
Most GLP-1 comparisons are indirect — separate placebo-controlled trials in different populations. This pair is unusual in having been tested against each other twice, once in diabetes and once in obesity.
SUSTAIN 10 (Diabetes & Metabolism, 2020) randomised 577 adults with type 2 diabetes 1:1 to semaglutide 1.0 mg weekly or liraglutide 1.2 mg daily as add-on to oral agents. From a baseline HbA1c of 8.2%, semaglutide lowered HbA1c by 1.7% against liraglutide's 1.0% (difference −0.69%, 95% CI −0.82 to −0.56, P<0.0001), and body weight by 5.8 kg against 1.9 kg (difference −3.83 kg, 95% CI −4.57 to −3.09, P<0.0001). The doses chosen matter to how you read it: 1.2 mg was the most commonly prescribed liraglutide dose in Europe at the time, not the 1.8 mg maximum on the Victoza label. This was a comparison of typical practice, not of ceiling doses.
STEP 8 (JAMA, 2022) removed that caveat. It ran 338 adults with overweight or obesity and without diabetes for 68 weeks at both drugs' approved maximum weight-management doses — semaglutide 2.4 mg weekly versus liraglutide 3.0 mg daily. Mean weight change was −15.8% versus −6.4%, a difference of 9.4 percentage points (95% CI −12.0 to −6.8, P<.001). The response-threshold numbers are starker than the means: 38.5% of the semaglutide group lost at least 20% of body weight, against 6.0% on liraglutide.
Both trials point the same direction on both endpoint families, which is the practical reason clinical discussion of liraglutide for weight has narrowed since 2022.
What each looks like against placebo
The placebo-controlled anchors are consistent with the direct comparisons. SCALE Obesity and Prediabetes (NEJM, 2015) randomised 3,731 participants 2:1 and reported 8.4 kg of mean weight loss on liraglutide 3.0 mg against 2.8 kg on placebo at 56 weeks — a landmark result when it published, and the basis for Saxenda's approval. STEP 1 (NEJM, 2021) then reported −14.9% versus −2.4% for semaglutide 2.4 mg over 68 weeks in 1,961 adults. Different trials, different populations, and percentages are not kilograms — but the ordering survives the direct comparison in STEP 8, which is the stronger evidence.
Cardiovascular outcomes
Here the two are closer, and liraglutide got there first. LEADER (NEJM, 2016) followed 9,340 adults with type 2 diabetes at high cardiovascular risk for a median 3.8 years. The composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 13.0% on liraglutide versus 14.9% on placebo (HR 0.87, 95% CI 0.78–0.97, P=0.01 for superiority), with cardiovascular death at HR 0.78 (95% CI 0.66–0.93). That trial is why Victoza carries a MACE-reduction indication alongside glycemic control.
SELECT (NEJM, 2023) asked a different question: 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes, followed a mean 39.8 months on semaglutide 2.4 mg. The composite occurred in 6.5% versus 8.0% on placebo (HR 0.80, 95% CI 0.72–0.90). The hazard ratios are in the same neighbourhood; the populations are not, so this is not a head-to-head cardiovascular result. What it changed is the size of the population with a labelled reason to be on a GLP-1 at all.
Tolerability: the counterintuitive part
A stronger drug is usually the harder one to stay on. STEP 8 found the opposite at maximum doses. Gastrointestinal adverse events were near identical — 84.1% with semaglutide, 82.7% with liraglutide — but discontinuation for any reason was 13.5% on semaglutide against 27.6% on liraglutide, roughly half. In SUSTAIN 10, at the lower comparison doses, the ordering flipped: gastrointestinal events were more common with semaglutide (43.9% vs 38.3%) and discontinuation was higher too (11.4% vs 6.6%). Dose and population, not molecule alone, drive that number.
The labelled risks are essentially the same document twice. Both carry a boxed warning for dose- and duration-dependent thyroid C-cell tumours in rodents, with human relevance undetermined; both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; both warn on pancreatitis, gallbladder events, and hypoglycemia when combined with insulin or sulfonylureas. See semaglutide side effects and liraglutide side effects for the fuller picture. One practical asymmetry follows from pharmacokinetics rather than toxicity: a 13-hour half-life washes out in days, while semaglutide remains in circulation for about five to seven weeks after the last dose, which is why its label instructs discontinuation at least two months before a planned pregnancy.
Oral options and the generic question
Semaglutide is the only one of the two available as a tablet. Rybelsus and Ozempic tablets are co-formulated with salcaprozate sodium (SNAC), an absorption enhancer that lets a 4-kDa peptide cross the gastric mucosa at all — absolute bioavailability is still only about 0.4% to 2%, which is why oral doses run in milligrams where injections run in fractions of one. Wegovy has since added a tablet form for weight reduction and cardiovascular risk reduction. No oral liraglutide is approved.
Liraglutide's distinguishing advantage now runs the other way. In December 2024 the FDA approved the first generic referencing Victoza, the first once-daily GLP-1 generic, prioritised partly because of shortage. Semaglutide has no US generic. A generation-older molecule with a more affordable supply path is a different kind of relevance than best efficacy, and it is the reason liraglutide remains in formularies rather than in history.
How to dive deeper
- Semaglutide overview · benefits · side effects · research
- Liraglutide overview · benefits · side effects · research
- Next comparison in the class: semaglutide vs tirzepatide — where a second incretin receptor, not a longer half-life, is the variable.
- Related questions: are GLP-1 drugs considered peptides? · how do weight-loss peptides work? · what peptide acts like Ozempic? · are GLP-1 peptides safe long term?
- Class context: GLP-1 receptor agonists · all comparisons
References
- Capehorn MS, et al. SUSTAIN 10: semaglutide 1.0 mg vs liraglutide 1.2 mg. Diabetes Metab. 2020. PMID 31539622.
- Rubino DM, et al. STEP 8: weekly semaglutide vs daily liraglutide on body weight. JAMA. 2022. PMID 35015037.
- Wilding JPH, et al. STEP 1: once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PMID 33567185.
- Pi-Sunyer X, et al. SCALE: 3.0 mg liraglutide in weight management. N Engl J Med. 2015. PMID 26132939.
- Marso SP, et al. LEADER: liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016. PMID 27295427.
- Lincoff AM, et al. SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. PMID 37952131.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019. PMID 31031702.
- DailyMed labels: Victoza · Saxenda · Ozempic · Wegovy · Rybelsus / Ozempic tablets.
- FDA. FDA approves first generic of once-daily GLP-1 injection. December 23, 2024.